Semaglutide FAQ: 50 Questions People Ask Google

Semaglutide is the most-searched prescription medicine in America, and most of the searching is people trying to get a straight answer to a short question. This page collects the fifty questions that come up most often and answers each one in a couple of sentences, with a source you can check.

A note before you start. This is a reference, not medical advice. Nothing here tells you whether to take semaglutide, which product to ask for, or what dose is right for you. Those are decisions for you and a healthcare provider who knows your history.

Last verified September 14, 2026. Prices and label details on this topic have changed repeatedly, so check the date before you rely on a number.

What is semaglutide, in plain English?

Semaglutide is a lab-made copy of a hormone your gut releases after you eat, called GLP-1 [1][31]. Natural GLP-1 breaks down in minutes. Semaglutide was engineered to last about a week, so one weekly injection keeps the signal switched on continuously.

That signal does three useful things. It tells the pancreas to release insulin when blood sugar is high. It slows how quickly food leaves the stomach, so you feel full longer. And it acts on appetite centers in the brain, which is why so many people describe the effect as the constant background chatter about food going quiet [1][31].

Which semaglutide products can you actually get in the US?

This is where most confusion starts. One ingredient, three brand identities, five products as of September 2026:

Product	Brand	How you take it	Approved for
Ozempic injection	Ozempic	Once weekly	Type 2 diabetes, heart risk reduction, chronic kidney disease
Ozempic tablets (1.5 / 4 / 9 mg)	Ozempic	Daily pill	Type 2 diabetes, heart risk reduction
Wegovy injection (0.25–2.4 mg)	Wegovy	Once weekly	Weight management (12 and up), heart risk reduction, MASH
Wegovy HD (7.2 mg)	Wegovy	Once weekly	Weight management in adults who tolerated 2.4 mg
Wegovy tablets (25 mg)	Wegovy	Daily pill	Weight management, heart risk reduction

The Rybelsus brand is being retired. The FDA approved the proprietary name change on February 4, 2026 and the reformulated tablets went on sale as Ozempic tablets on May 4, 2026 [13]. Novo Nordisk stopped shipping Rybelsus to wholesalers in May 2026, and remaining inventory began running out from July 2026. One detail worth knowing: the FDA prescribing information is still a single combined document covering both “Rybelsus and Ozempic tablets,” and it states plainly that the two are not substitutable on a milligram-to-milligram basis [4]. So if you have an old Rybelsus prescription for 7 mg, the equivalent in the new range is not the same number, and that is a conversation to have with your pharmacist or prescriber.

Two more products get mentioned constantly and are not semaglutide. Mounjaro and Zepbound are tirzepatide, a different molecule made by Eli Lilly. Foundayo is orforglipron, also Eli Lilly, a pill approved on April 1, 2026 [35]. They are worth knowing about, but they are not interchangeable with semaglutide and nothing in this article applies to them.

How much weight do people actually lose?

The headline trial number is 14.9 percent. In STEP 1, adults with obesity and without diabetes who took 2.4 mg weekly for 68 weeks lost an average of 14.9 percent of their body weight, compared with 2.4 percent on placebo [5]. For someone starting at 230 pounds, that is roughly 34 pounds.

The honest number is lower. A Cleveland Clinic analysis of 7,881 real patients found average weight loss of about 8.7 percent at one year [23]. The gap is not mysterious. In that cohort, people who stopped within three months lost 3.6 percent, people who stopped later lost 6.8 percent, and people who stayed on treatment lost 11.9 percent. More than 80 percent never got past a low maintenance dose.

So the realistic framing is: trial results are what happens when you stay on the drug and reach a full dose. Real-world results are what happens on average, including everyone who could not afford it, could not tolerate it, or lost coverage.

What happens if you stop?

This is the question with the least comfortable answer. In the STEP 1 extension, participants who stopped after 68 weeks regained about two-thirds of the weight they had lost within a year, and the improvements in blood pressure, cholesterol and blood sugar drifted back toward where they started [6].

That does not mean stopping is pointless or that everyone regains everything. It means the drug works while you take it, the way blood pressure medicine does, and stopping is a decision worth planning with a provider rather than making abruptly because a refill ran out.

What are the side effects, and which ones matter?

Almost everyone who has side effects has stomach side effects: nausea, vomiting, diarrhea, constipation, stomach pain, burping and gas [2][3]. They cluster around dose increases and settle down at a steady dose for most people. Constipation is the one most likely to persist.

The uncommon but serious list is shorter and more specific. The labels name pancreatitis, gallbladder disease including gallstones, acute kidney injury caused by dehydration from severe vomiting or diarrhea, serious allergic reactions, worsening of existing diabetic eye disease, and severe gastrointestinal reactions [2][3]. A Harvard and CDC analysis concluded that serious side effects are uncommon [30], which is reassuring without meaning they never happen.

Three things change dose-dependently, which is worth knowing before anyone asks to move up. In STEP UP, gastrointestinal side effects occurred in 70.8 percent of people on 7.2 mg versus 61.2 percent on 2.4 mg, and an odd skin sensation called dysesthesia jumped from 6.0 percent to 22.9 percent [8].

Every semaglutide product carries a boxed warning about thyroid C-cell tumors seen in rodents [2]. Whether it happens in humans is unknown. What is not ambiguous is the contraindication: nobody with a personal or family history of medullary thyroid carcinoma, or with MEN 2 syndrome, should take it.

One label change is worth flagging because most websites have not caught up. On January 13, 2026 the FDA asked manufacturers to remove the suicidal behavior and ideation warning from GLP-1 labels after a multi-year review [20]. If you read a page that still describes that warning as current, the page is out of date.

And one gap runs the other way. European regulators classified NAION, a sudden and usually permanent loss of vision in one eye, as a very rare side effect affecting up to 1 in 10,000 people in June 2025 [19]. The UK’s MHRA followed in February 2026 and Australia’s TGA in July 2026. As of September 14, 2026, the US labels still do not carry that warning. That difference is a central allegation in the federal NAION litigation, MDL 3163 [26].

What does it cost, and why does every website say something different?

Because there are at least five different prices and most pages do not say which one they are quoting.

• List price. What the manufacturer sets. Ozempic was $1,027.51 a month in 2026 [14].
• Retail cash price. What a pharmacy charges with no discount, often above list, sometimes over $1,200 [15].
• Manufacturer self-pay price. Novo Nordisk’s direct price: roughly $199 to $499 a month for the injection depending on dose and whether you are new, and $149 to $299 for the tablets [14].
• Coupon or discount card price. Varies by card and pharmacy.
• Insured copay. Can be as low as $25 a month with a commercial plan that covers the drug, or nothing at all if the plan excludes it.

Two changes are scheduled. Novo Nordisk announced on February 24, 2026 that list prices would drop to $675 a month on January 1, 2027 [17]. And since July 1, 2026, the Medicare GLP-1 Bridge has offered eligible Part D enrollees certain GLP-1 drugs for obesity at a $50 monthly copay, running through the end of 2027 [16]. TrumpRx.gov, launched February 2026, shows federal cash prices and issues coupons, but it is a coupon site rather than a pharmacy and its prices cannot be combined with insurance [18].

For context on why any of this is expensive: a Peterson-KFF analysis found the US list price for a month of Ozempic was more than five times the price in Japan and roughly ten times the price in several European countries [29].

Is compounded semaglutide the same thing?

No, and this is the single most consequential misunderstanding on the topic.

Compounded semaglutide is made by a compounding pharmacy rather than the manufacturer. It is not FDA approved, which means no agency reviewed it for safety, effectiveness or manufacturing quality before it was sold [24][25]. It is also not a generic: a generic has to prove it is equivalent to the brand, and no US generic semaglutide has launched. Apotex, working with Orbicular, received the first tentative FDA approval for generic semaglutide injection on April 10, 2026, which means the application met the agency’s standards but cannot be marketed until the patent and exclusivity barriers clear. The main US patent on Ozempic runs to 2032, so a tentative approval is not a signal that a cheap generic is close [28].

Compounding was widely permitted while semaglutide was in official shortage. The FDA declared that shortage resolved on February 21, 2025, and the enforcement discretion that had allowed compounders to make copies ended in April 2025 for state-licensed pharmacies and May 2025 for outsourcing facilities. The space has kept narrowing since: on February 6, 2026 the FDA announced it would restrict GLP-1 active ingredients destined for mass-marketed compounded products, on March 3, 2026 it issued 30 warning letters to telehealth companies whose marketing implied their compounded product was equivalent to the approved drug, and on April 1, 2026 it confirmed that neither semaglutide nor tirzepatide appears on the drug shortage list or the 503B bulks list [24][25]. If you are researching this, check a dated source, because the answer in January was not the answer in July.

What else is semaglutide approved to do?

The label has widened a long way past blood sugar:

• Heart. In SELECT, 17,604 adults with cardiovascular disease and excess weight but no diabetes had about a 20 percent lower risk of cardiovascular death, heart attack or stroke over roughly three and a half years [7]. That result is why Wegovy carries a cardiovascular indication, and why Medicare Part D can cover it for that use at all.
• Kidneys. In FLOW, people with type 2 diabetes and chronic kidney disease had a 24 percent lower risk of major kidney events. The trial was stopped early because the benefit was clear [22].
• Liver. Wegovy injection received accelerated approval in August 2025 for adults with noncirrhotic MASH and moderate to advanced fibrosis, the first GLP-1 approved for that condition [21].
• Alcohol. A 2026 Lancet trial found semaglutide reduced heavy drinking days in people with alcohol use disorder and obesity [32]. It is not approved for that, and it is being studied, not prescribed for it routinely.

When should you call a healthcare provider?

Not for ordinary nausea in week two. Do contact a provider promptly for severe or persistent stomach pain, especially pain that radiates to your back; vomiting or diarrhea bad enough that you cannot keep fluids down; sudden vision changes in one eye; signs of a serious allergic reaction; or symptoms of gallbladder trouble such as pain in the upper right abdomen with fever or yellowing skin [2][3].

Tell every clinician you see that you take it, and say so well before any procedure involving anesthesia or sedation, because the slowed stomach emptying matters there [3].

Sources

1. Drugs.com, Semaglutide — https://www.drugs.com/semaglutide
2. FDA, Wegovy prescribing information — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
3. DailyMed, Ozempic prescribing information — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
4. FDA, oral semaglutide prescribing information — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf
5. NEJM, STEP 1 — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
6. PubMed, STEP 1 off-treatment extension — https://pubmed.ncbi.nlm.nih.gov/35441470/
7. PubMed, SELECT — https://pubmed.ncbi.nlm.nih.gov/37952131/
8. PubMed, STEP UP — https://pubmed.ncbi.nlm.nih.gov/40961953/
9. PubMed, OASIS 4 — https://pubmed.ncbi.nlm.nih.gov/40934115/
10. NEJM, SURMOUNT-5 — https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
11. FDA, Wegovy HD approval announcement — https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
12. AJMC, FDA approves oral semaglutide for weight loss — https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss
13. FDA, Ozempic tablets name change approval letter — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf
14. Drugs.com, Ozempic cost with and without insurance — https://www.drugs.com/medical-answers/what-ozempic-cost-insurance-without-insurance-3578680/
15. GoodRx, How much Ozempic costs without insurance — https://www.goodrx.com/ozempic/how-to-save-on-ozempic
16. CMS, Medicare GLP-1 Bridge — https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
17. Novo Nordisk, US list price reduction — https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html
18. TrumpRx.gov — https://trumprx.gov/
19. EMA, PRAC conclusion on NAION — https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
20. FDA, request to remove suicidal behavior and ideation warning — https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
21. Novo Nordisk, Wegovy MASH approval — https://www.prnewswire.com/news-releases/wegovy-approved-by-fda-for-the-treatment-of-adults-with-noncirrhotic-mash-with-moderate-to-advanced-liver-fibrosis-302531394.html
22. PubMed, FLOW — https://pubmed.ncbi.nlm.nih.gov/38785209/
23. PubMed, Gasoyan et al., real-world weight outcomes — https://pubmed.ncbi.nlm.nih.gov/40491239/
24. FDA, compounding policies as GLP-1 supply stabilizes — https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
25. FDA, concerns with unapproved GLP-1 drugs — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
26. Drugwatch, Ozempic lawsuit status — https://www.drugwatch.com/legal/ozempic-lawsuit/
27. PubMed, STEP TEENS — https://pubmed.ncbi.nlm.nih.gov/36322838/
28. Drug Topics, tentative approval of generic semaglutide — https://www.drugtopics.com/view/fda-tentatively-approves-generic-version-of-semaglutide
29. Peterson-KFF, prices of weight loss drugs in the US and peer nations — https://www.healthsystemtracker.org/brief/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations/
30. Harvard Health, serious side effects from semaglutide are uncommon — https://www.health.harvard.edu/healthy-aging-and-longevity/harvard-and-cdc-study-serious-side-effects-from-semaglutide-are-uncommon
31. Mayo Clinic, semaglutide (subcutaneous route) — https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730
32. The Lancet, semaglutide in alcohol use disorder — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext
33. PMC, systematic review of facial changes after GLP-1 weight loss — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232544/
34. PMC, STEP 1 body composition sub-study — https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287
35. FDA, first new molecular entity approved under the National Priority Voucher program — https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program